Table 5.
Meta-analysis of Edoxaban Trials
| Trial | Year | Regimen | No. of Patients Randomized | Treatment Duration | No. of VTEs | RR VTE* | No. of Major Bleeds | RR major bleeding* | No. of Major/Clinically Relevant Bleeds | RR Major/Clinically Relevant Bleeding* |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| STARS E-3 | 2014 | Edoxaban 30 mg QD | 360 | 11–14 days | 22 | 0.53 (0.32–0.87) | 4 | 3.94 (0.44–35.11) | 22 | 1.67 (0.85–3.26) |
| Enoxaparin 20 mg BID | 365 | 41 | – | 1 | – | 13 | – | |||
|
| ||||||||||
| STARS J-V | 2015 | Edoxaban 30 mg QD | 307 | 11–14 days | 6 | 0.34 (0.14–0.86) | 2 | 0.33 (0.07–1.63) | 8 | 0.72 (0.29–1.77) |
| Enoxaparin 20 mg BID | 303 | 17 | – | 6 | – | 11 | – | |||
|
| ||||||||||
| Meta-analysis | 2014–2015 | Edoxaban 30 mg QD | 667 | 11–14 days | 28 | 0.49 (0.32–0.75) | 6 | 1.58 (0.05–54.38) | 30 | 1.33 (0.53–3.34) |
| Enoxaparin 20 mg BID | 668 | 58 | – | 7 | – | 24 | – | |||
*
RR compared to enoxaparin. Values in parentheses denote a 95% confidence interval.
Abbreviations: RR, relative risk; VTE, venous thromboembolism